investors & media

There are currently no events to display.

corporate profile

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit. bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders: cerebral adrenoleukodystrophy, sickle cell disease, β-thalassemia and multiple myeloma, using gene and cell therapy technologies including gene addition, and (megaTAL-enabled) gene editing. bluebird bio has an additional nest in Seattle, Wash.

stock quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

press releases


CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 18, 2021-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect the separation of bluebird

Read more

 - Company shares detail on stock distribution ratio and planned cash allocation - - New board members appointed - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 8, 2021-- bluebird bio, Inc. (NASDAQ: BLUE) today announced the filing by 2seventy bio of an updated Form 10 Registration Statement with the

Read more

BLA submission based on data from Phase 1/2 and Phase 3 Northstar studies, which represent more than 220 patient-years of experience with beti-cel CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 21, 2021-- bluebird bio, Inc . (Nasdaq: BLUE) today announced it has completed the rolling submission of its

Read more